IQRx® combines the latest molecular technology (the pharmacogenomic test) with Resolve Health’s proprietary data analytics and risk stratification algorithm.  IQRx® can quickly analyze each employee and the medicine that would have a high probability of working based on his/her genetics. IQRx® focuses on 4 important drug classes: pain, cardiovascular, diabetes, and behavioral health. 


Its easy to collect, analyze & implement the data from IQRx®: 

Impact of IQRx® for the Self-Insured Employer:

          Increase employee productivity

          Decrease overall employer spend by reducing unnecessary physician visits

          Increase employee well-being and health

          Decrease absenteeism

          Decrease overall employer pharmacy spend by decreasing the usage of unnecessary medications 

A person's "pharmacogenetics formulary" is unique to that person:  Drill down on each patient to determine where each applicable medicine fits into their individual pharmacogenetic profile...BEFORE prescribing a medication.

Pharmacy costs are increasing more rapidly than any other medical benefit cost (13.1% year on year, Express Scripts 8/31/15). In 2017, the expectation is that pharmacy costs will exceed 30% of the total medical benefit for employees. 

Select a person's medication history to review as compared to their individual pharmacogenetic profile.

“According to the National Institute of Mental Health, the leading cause of absenteeism in the United States is depression.”
- Forbes, July 10, 2013

"Unscheduled absenteeism is a chronic problem for US employers, conservatively costing $3,600 per hourly employee per year, and $2,650 per salaried employee per year."
- CIRCADIAN’s Shiftwork practices, 2005 

Ensure that current and future medications are personalized for every employee or patient by contacting Resolve Health today:

615-800-8471                support@resolve-health.com 

Trial-and-error prescribing of the past is not an efficient approach for both patient and payor.
IQRx® allows a healthcare provider to use Resolve's pharmacogenomic test / result as a decision support tool to assist in choosing the right drug, at the right dose, and given at the right frequency for each patient. This 'one-and-done' approach replaces the long-standing trial-and-error approach to prescribing medicines. The information collected from a pharmacogenomic test can be used over a lifetime, making it beneficial and cost-effective.

What is IQRx®?
 IQRx®  is INTELLIGENT PRESCRIBING, a targeted medication management solution.  IQRx® is a proprietary program that identifies the candidates for testing based on their current medications, the relevance  of pharmacogenomics to the metabolism and response of those medications and the level of evidence behind the research supporting such use.  IQRx® results then allows your pharmacogenomic profile to forever be available to ensure the most appropriate medication is prescribed for each individual patient, integrated into either pharmacy management software or your EHR.​

Use pharmacogenetic profiles in a dynamic, real time manner 

As pharmacy costs continues to increase, trial-and-error becomes even more costly in the list of healthcare burdens. ​ After a simple cheek swab, IQRx® brings together a patient’s pharmacogenomic profile with clinical and economic analytics to validate both medication choice and the reduction in overall healthcare spend.

Resolve Health believes that testing is both an intervention and a preventative strategy. The introduction of IQRx® at any stage of an employee’s tenure with the company will provide significant value to the employee and the employer.

A Medication Management Program should:
                       • Optimize drug therapies                         • Personalize Prescription Management
             • Minimize adverse drug effects and Drug-Gene interactions          • Maximize drug efficacy

IQRx® Patient Pool Overview: Review an overall breakdown of how many in your institution may be most at risk of Adverse Drug Reactions (ADRs) as it relates to each individual's pharmacogenetics profile.